生物技术公司Apnimed（APMD）今日盘中股价大涨37.5%，引发市场广泛关注。
消息面上，该公司今日在纳斯达克正式挂牌上市。此前，Apnimed将IPO发行价定在每股16美元，超出14至16美元的初始定价区间上限，并将发行规模从原计划的1000万股扩大至1200万股，最终募资1.92亿美元。强劲的IPO定价和扩大的发行规模，反映出市场对其投资价值的高度认可，推动股价开盘后大幅走高，最新显示股价达到22美元，远超发行价。
Apnimed总部位于马萨诸塞州剑桥市，是一家处于后期研发阶段的生物技术公司。其唯一临床候选药物AD109是一种每日一次的口服药物，用于治疗阻塞性睡眠呼吸暂停，该病症影响全球数亿人，市场空间广阔。公司大股东包括Morningside、Alpha Wave Ventures和日本盐野义制药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.